Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Inclusion Criteria:

• Has not yet had coitarche and does not plan on becoming sexually active during thevaccination period

• Participant or participant's legally acceptable representative can read, understand,and complete the electronic vaccination report card (eVRC).

Exclusion Criteria:

• Known allergy to any vaccine component

• History of severe allergic reaction that required medical intervention

• Thrombocytopenia or any coagulation disorder

• Has a history of myocarditis or pericarditis

• Has a history of a clinical or microbiological diagnosis of COVID-19 ≤90 days priorto Day 1 visit or history of multisystem inflammatory syndrome in children (MIS-C)at any time prior to Day 1 visit

• Females only: participant is pregnant

• Currently immunocompromised, or been diagnosed with immunodeficiency

• Had a splenectomy

• Receiving or has received immunosuppressive therapies within the last year

• Received any immunoglobulin product or blood-derived product within 3 months

• Received a marketed HPV vaccine or has participated in an HPV vaccine clinical trial